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A B S T R A C T
Despite recent developments in various therapies, heart failure remains a leading cause of morbidity and
mortality worldwide. New pharmacological approaches are therefore needed to improve the outcomes of
patients with heart failure. Diabetes mellitus is an important risk factor for heart failure, but until recently
there had been no evidence that hypoglycemic agents prevent heart failure. Sodium-glucose cotransporter-
2 (SGLT2) inhibitors have now been shown to prevent cardiovascular events, especially hospitalization for
heart failure, in three large randomized clinical trials: EMPA-REG OUTCOME, the CANVAS program, and the
DECLARE-TIMI58 trial. It isexpected,therefore, that SGLT2inhibitorswillbeusefultherapeuticagents forthe
treatment of heart failure. The DAPA-HF trial recently demonstrated that dapagliflozin significantly reduces
cardiovasculardeath and hospitalization forheart failure inpatientswith heart failurewith reduced ejection
fraction (HFrEF). Importantly, these benefits of dapagliflozin were similarly observed in patients with or
without diabetes, suggesting the drug's efficacy is independent of glycemic reduction. The results of that
study highlight the significance of SGLT2 inhibition as a novel therapeutic approach to treating HFrEF,
irrespective of the presence or absence of diabetes. Findings of the DAPA-HF trial may also challenge current
assumptions about the mechanisms underlying the cardioprotective action of SGLT2 inhibitors. It is
anticipated that ongoing clinical trials, mainly using dapagliflozin and empagliflozin, will provide further
insight into the clinical importance of these drugs for the treatment of heart failure, including heart failure
with preserved ejection fraction (HFpEF), and also the mechanisms underlying those clinical benefits.
© 2020 Published by Elsevier Ltd on behalf of Japanese College of Cardiology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Background
Despite recent progress in both pharmacological and non-
pharmacological interventions, heart failure remains a leading
cause of morbidity and mortality worldwide. Heart failure is
caused by various cardiovascular diseases, often stemming from
other illnesses. Diabetes mellitus, for example, is an important risk
factor for cardiovascular disease, and the incidence of cardiovas-
cular events is significantly higher in diabetic patients than in non-
diabetic patients [1]. Heart failure is also one of the most common
complications of type 2 diabetes mellitus (T2DM). Indeed, the
incidence of heart failure among patients with T2DM is reportedly
2- to 5-fold greater than in the general population [2], and the risk
of heart failure increases with an increase in HbA1c in T2DM
patients [3]. Thus, in the treatment of T2DM, preventing the onset
and progression of cardiovascular diseases that ultimately lead to
heart failure is considered to be important. However, there has
been no large-scale clinical study showing that tight glycemic
control leads to early improvement in macrovascular outcomes in
patients with T2DM. Moreover, no glucose-lowering agent has
been clearly shown to prevent the onset or improve the outcomes
of heart failure in patients with T2DM [4–6]. Until recently, heart
failure had evidently been “the frequent, forgotten, and often fatal
complication of T2DM” [7].
Against that background, the Empagliflozin Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-
REG OUTCOME) demonstrated that empagliflozin, a sodium-
glucose cotransporter-2 (SGLT2) inhibitor, significantly reduced
the incidence of cardiovascular events among T2DM patients
[8]. In that study, the cardiovascular benefits of empagliflozin
were manifested in particular as significant reductions in
cardiovascular death and hospitalization for heart failure. Later,
the Canagliflozin Cardiovascular Assessment Study (CANVAS)
program and the Dapagliflozin Effect on Cardiovascular Events –
Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI58) trial
showed similar trends toward reducing hospitalization for heart
failure, which suggests prevention of heart failure is a class effect
for SGLT2 inhibitors. Based on those results, further exploration of
the therapeutic potential of SGLT2 inhibitors on the outcomes of
heart failure patients, irrespective of the presence or absence of
T2DM, was expected. The Study to Evaluate the Effect of
Dapagliflozin on the Incidence of Worsening Heart Failure or
Cardiovascular Death in Patients With Chronic Heart Failure
(DAPA-HF) reported in 2019 that dapagliflozin reduces the
incidence of major cardiovascular events in patients with
established heart failure with reduced ejection fraction (HFrEF)
[9]. Importantly, it was also found that the magnitude of the
benefit of dapagliflozin was similar in patients with or without
T2DM.
In this review, we summarize the effects of SGLT2 inhibitors on
cardiovascular outcomes derived from large-scale, randomized
clinical trials, focusing especially on their beneficial effects on the
prevention of heart failure onset and progression. We also describe
what are thought to be likely mechanisms underlying the
beneficial effects of SGLT2 inhibitors.
Prevention of cardiovascular events, including heart failure, by
SGLT2 inhibitors in patients with T2DM
Since 2008, the US Food and Drug Administration has required
safety assessment for diabetes treatments, mandating large-scale
clinical trials to prove that the treatment does not increase
cardiovascular events. Consequently, the SGLT2 inhibitors empa-
gliflozin, canagliflozin, and dapagliflozin have been the subject of
several large-scale, randomized, clinical trials to prove their
noninferiority to placebo for cardiovascular events. In addition
to their noninferiority, SGLT2 inhibitors exerted beneficial effects
preventing cardiovascular events. The details of these clinical trials
are summarized below.
EMPA-REG outcome
This study was designed to compare the cardiovascular safety of
the SGLT2 inhibitor empagliflozin with placebo during glucose-
lowering therapy administered against a background of standard
treatment to adults with T2DM who were at high cardiovascular
risk. It was performed as a randomized, double-blind, placebo-
controlled trial. A total of 7020 patients with T2DM (glycated
hemoglobin level, 37.0% and 29.0%), which included adults (318
years of age) with an estimated glomerular filtration rate (eGFR) of
at least 30 ml/min/1.73 m2 of body-surface area and had estab-
lished cardiovascular disease, were randomly assigned to receive
10 mg or 25 mg of empagliflozin or placebo. The primary
composite outcome was death from cardiovascular causes,
nonfatal myocardial infarction, or nonfatal stroke, which is the
so-called 3-point major adverse cardiovascular events (MACE), as
analyzed in the pooled empagliflozin group versus the placebo
group. Primary composite outcomes occurred in 490 of the
4687 patients (10.5%) in the empagliflozin group and in 282 of
the 2333 patients (12.1%) in the placebo group (hazard ratio in the
empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99;
p = 0.04 for superiority). In addition, the empagliflozin group had
significant lower rates of death from any cause (5.7% vs. 8.3% in the
placebo group; 32% risk reduction) and from cardiovascular causes
(3.7% vs. 5.9%; 38% relative risk reduction). The empagliflozin
group also had a significantly lower rate of hospitalization for heart
failure (2.7% vs. 4.1%; 35% relative risk reduction). On the other
hand, no significant differences were detected in the rates of
myocardial infarction or stroke between the two groups.
Exploratory mediation analysis in this trial showed that
changes in hematocrit and hemoglobin respectively mediated
51.8% and 48.9% of the effect of empagliflozin on the risk of
cardiovascular death, indicating that changes in markers of plasma
volume were the most important mediators of the reduction of
cardiovascular death with empagliflozin [10].
The CANVAS program
The CANVAS program integrated data from two trials, CANVAS
and CANVAS-R, which involved a total of 10,142 participants with
T2DM and high cardiovascular risk [11]. Participants in CANVAS
were randomly assigned in a 1:1:1 ratio to receive canagliflozin at a
dose of 300 mg, canagliflozin at a dose of 100 mg, or a matching
placebo, while participants in CANVAS-R were randomly assigned
in a 1:1 ratio to receive canagliflozin at an initial dose of 100 mg
daily with an optional increase to 300 mg starting from week 12 or
matching placebo. The total canagliflozin group contained
5795 participants, while the placebo group had 4347 participants.
The primary outcome was 3-point MACE. Participants were men
and women (330 years of age) with T2DM (glycated hemoglobin
level, 37.0% and 210.5%) and eGFR 330 ml/min/1.73 m2 of body
surface area at entry. All participants also had a history of
symptoms of atherosclerotic cardiovascular disease or risk factors
for cardiovascular disease. In this study, risk factors were defined
as T2DM for at least 10 years, systolic blood pressure >140 mmHg
while receiving one or more antihypertensive agents, current
smoking, microalbuminuria or macroalbuminuria, or high-density
lipoprotein (HDL) cholesterol level of less than 1 mmol/l (38.7 mg/
dl). The numbers of participants with a history of cardiovascular
disease were 3756 (64.8%) in canagliflozin group and 2900 (66.7%)
in the placebo group. In this trial, therefore, 3486 (34%)
participants who had cardiovascular risk factors, but not a
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cardiovascular disease, were assessed for primary prevention of
cardiovascular disease [11].
A total of 9734 participants completed the trial. Significantly
fewer participants in the canagliflozin group than in the placebo
group had a primary outcome event (3-point MACE): 26.9 vs.
31.5 participants with an event per 1000 patient-years (HR, 0.86;
95% CI, 0.75 to 0.97; p < 0.001 for noninferiority; p = 0.02 for
superiority). Superiority was not shown for the first secondary
outcome in the testing sequence (death from any cause; p = 0.24),
and hypothesis testing was discontinued. Consequently, estimates
for fatal secondary outcomes, including death from any cause (HR,
0.87; 95% CI, 0.74 to 1.01) or from cardiovascular causes (HR, 0.87;
95% CI, 0.72 to 1.06), are not considered to be significant. However,
the results also showed that patients treated with canagliflozin had
a lower risk of hospitalization for heart failure than patients who
received placebo, which was similar to the results of EMPA-REG
OUTCOME.
In addition, the results of a comparison between primary and
secondary prevention were reported in 2018 [12]. The primary end
point event rate was higher in the secondary prevention group
than the primary prevention group (36.9 vs. 15.7/1000 patient-
years, p < 0.001). Among the total cohort, the primary endpoint
was lower with canagliflozin than with placebo (26.9 vs. 31.5/1000
patients-years; HR, 0.86; 95% CI, 0.75–0.97; p < 0.001 for no
inferiority, p = 0.02 for superiority), with no statistical evidence of
heterogeneity (interaction p-value = 0.18) between the primary
(HR, 0.98; 95% CI, 0.74–1.30) and secondary (HR, 0.82; 95% CI, 0.72–
0.95) prevention cohorts. Regarding hospitalization for heart
failure, there was no statistical evidence of heterogeneity between
the primary and secondary prevention cohorts (interaction p-
value = 0.91).
DECLARE-TIMI58
The DECLARE-TIMI58 trial included 17,160 patients (340 years
of age) with T2DM (glycated hemoglobin level, 36.5% and 212.0%)
with eGFR 360 ml/min/1.73 m2 of body surface area [13]. Eligible
patients also had multiple risk factors for atherosclerotic
cardiovascular disease (ASCVD) or had established ASCVD.
Multiple risk factors (MRF) were being a man 55 years of age or
older or a woman 60 years of age or older with one or more
traditional risk factors, including hypertension, dyslipidemia
(defined as a low-density lipoprotein cholesterol level >130 mg/
dl or the use of lipid-lowering therapy), or use of tobacco. These
enrollment criteria suggest that many of the participants in this
study were at lower risk than those in the EMPA-REG OUTCOME or
the CANVAS program. This study included patients for both
secondary (40.6%, n = 6974) and primary (59.4%, n = 10,186)
prevention of cardiovascular diseases. The ratio of patients for
primary prevention of cardiovascular diseases within the total
participants in the study was higher than in two previously
discussed studies.
The patients were randomly assigned to receive 10 mg of
dapagliflozin (n = 8582) or placebo (n = 8578). The primary safety
outcome was 3-point MACE. The primary efficacy outcomes were
3-point MACE and a composite of cardiovascular death or
hospitalization for heart failure. This is the first trial using SGLT2
inhibitors in which hospitalization for heart failure was included in
a primary endpoint. Secondary efficacy outcomes were a renal
composite (340% decrease in eGFR to <60 ml/minute/1.73 m2 of
body-surface area, new end-stage renal disease, or death from
renal or cardiovascular causes) and death from any cause.
The 17,160 participants included 10,186 without ASCVD who
were followed for a median of 4.2 years. In the primary safety
outcome analysis, dapagliflozin met the prespecified criterion for
noninferiority to placebo with respect to MACE (upper boundary of
the 95% CI, <1.3; p < 0.001 for noninferiority). In the two primary
efficacy analyses, dapagliflozin did not result in a lower rate of MACE
(8.8% in the dapagliflozin group and 9.4% in the placebo group; HR,
0.93; 95% CI, 0.84 to 1.03: p = 0.17). However, dapagliflozin did result
in a lower rate of cardiovascular death or hospitalization for heart
failure than placebo (4.9% vs. 5.8%; HR, 0.83; 95% CI, 0.73–0.95;
p = 0.005). This reflected a lower rate of hospitalization for heart
failure (HR, 0.73; 95% CI, 0.61 to 0.88); there was no between-group
difference in cardiovascular death (HR, 0.98; 95% CI, 0.82 to 1.17). This
efficacy of dapagliflozin for cardiovascular death or hospitalization
for heart failure was similar in the subgroup of patients with
established ASCVD (7.8% in the dapagliflozin group and 9.3% in the
placebo group; HR, 0.83; 95% CI, 0.71–0.98) and in the subgroup of
patients with MRF for primary prevention (2.8% in the dapagliflozin
group and 3.4% in the placebo group; HR, 0.84; 95% CI, 0.67–1.04;
p = 0.99 for interaction).
A sub-analysis of the impact of baseline left ventricular ejection
fraction (LVEF) on the clinical benefit of dapagliflozin was recently
published by Kato et al. [14]. Of the 17,160 participants in the
DECLARE-TIMI 58 trial, 671 (3.9%) with HFrEF, 1316 (7.7%) with
heart failure with preserved EF (HFpEF), and 15,173 (88.4%) had no
history of heart failure at baseline. Dapagliflozin also reduced
cardiovascular death or hospitalization for heart failure more in
patients with HFrEF (HR 0.62, 95% CI, 0.45–0.86) than in those with
HFpEF (HR, 0.88; 95% CI, 0.76–1.02; p-interaction 0.046). Dapagli-
flozin reduced hospitalization for heart failure in those with HFrEF
(HR, 0.64; 95% CI, 0.43–0.95) and with HFpEF (HR, 0.76; 95% CI,
0.62–0.92) [14]. Moreover, a recent analysis revealed that
dapagliflozin consistently reduced the risk of atrial fibrillation
and atrial flutter (AF/AFL) events (HR, 0.81; 95% CI, 0.68–0.95,
p = 0.009), irrespective of the presence or absence of a history of
AF/AFL at baseline [15]. The presence of ASCVD versus MRF, or a
history of heart failure did not modify the reduction in AF/AFL
events observed with dapagliflozin [15].
Zelniker et al. reported a meta-analysis of all three trials of
SGLT2 inhibitors described above, in which a total of 34,322
patients (60.2% with established ASCVD) were analyzed [16]. SGLT2
inhibitors reduced MACE by 11% (HR, 0.89; 95% CI, 0.83–0.96);
p = 0.0014), with benefit seen only in patients with ASCVD; no
benefit was seen in those with MRF. On the other hand, SGLT2
inhibitors also reduced the risk of the composite of cardiovascular
death or hospitalization for heart failure by 23% (HR, 0.77; 95% CI,
0.71–0.84; p < 0.0001) with similar benefits in those with or
without ASVCD. The effect on hospitalization for heart failure alone
was particularly robust, with a 31% reduction in relative risk among
all patients (HR, 0.69; 95% CI, 0.61–0.79; p < 0.0001), a 29%
reduction in relative risk in the ASCVD group for secondary
prevention (HR, 0.71; 95% CI, 0.62–0.82; p < 0.0001), and a 36%
reduction in relative risk in the MRF group for primary prevention
(HR, 0.64; 95% CI, 0.48–0.85; p = 0.0021) [16].
SGLT2 inhibition as a novel therapeutic approach to HFrEF – the
DAPA-HF trial –
The three landmark trials discussed above show the prevention
of heart failure onset by SGLT2 inhibitors in T2DM patients at high
cardiovascular risk, which raises a question as to whether these
agents improve clinical outcomes in patients with heart failure,
irrespective of the absence or presence of T2DM.
DAPA-HF, a large-scale, placebo-controlled, randomized clinical
trial of SGLT2 inhibitors for HFrEF, answered that question. In this
study, 4744 patients with New York Heart Association (NYHA) class
II, III, or IV heart failure, EF 240%, and eGFR330 ml/min/1.73 m2
were enrolled and received either dapagliflozin (at a dose of 10 mg
once daily) or placebo in addition to the required standard devices
and drug therapy for heart failure. Among these patients were
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1096 Asian participants (343 Japanese participants). Non-diabetic
patients accounted for 58.2% of the participants, 96% were taking a
b-blocker, 71% had MRA. The principal cause of the heart failure
was ischemia in 55.5%, while the cause was nonischemic in 36.1%.
LVEF was 31.2  6.7%, median N-terminal prohormone B-type
natriuretic peptide (NT-proBNP) was 1428 (857–2655) pg/ml, and
67.7% were NYHA class II. The primary outcome was a composite of
worsening heart failure (hospitalization or an urgent visit resulting
in intravenous therapy for heart failure) or cardiovascular death.
The primary outcome occurred in 386 of the 2373 patients
(16.3%) in the dapagliflozin group and in 502 of the 2731 patients
(21.1%) in the placebo group (HR, 0.74; 95% CI, 0.65–0.85;
p < 0.001). A first worsening heart failure event occurred in
237 patients (10.0%) in the dapagliflozin group and in 326 patients
(13.7%) in the placebo group (HR, 0.70; 95% CI, 0.59–0.83). Adverse
events included major hypoglycemia (0.2% in both the dapagli-
flozin and placebo groups), amputation (0.5% vs. 0.5%), and diabetic
ketoacidosis (0.1% vs. 0%). There was no notable excess of any event
in the dapagliflozin group.
The effect of dapagliflozin on the primary outcome was
generally consistent across prespecified subgroups, including
patients without T2DM at baseline (with T2DM HR, 0.75; CI
0.63–0.90, without T2DM HR, 0.73; CI, 0.57–088). The patients in
NYHA functional class III or IV appeared to receive less benefit than
those in class II. However, findings with other subgroups that also
reflected more advanced disease (e.g. more reduced EF, poorer
renal function, and higher NT-proBNP level) were not consistent
with the finding for NYHA class. It will be necessary to wait for
further evaluation to clarify which patient conditions are more
affected by administration of a SGLT2 inhibitor and the reasons.
Another small clinical trial of dapagliflozin for heart failure
patientswasreported recently. The DEFINE-HF (Dapagliflozin Effects
on Biomarkers, Symptoms and Functional Status in Patients with HF
with Reduced Ejection Fraction) trial was a multicenter, randomized,
controlled trial of heart failure patients with LVEFs 240%, NYHA
classes II-III, eGFR 330 ml/min/1.73 m2, and elevated natriuretic
peptides [17]. The 263 enrolled patients were randomized to
dapagliflozin 10 mg daily or placebo groups for 12 weeks. The two
primary outcomes were (1) mean NT-proBNP and (2) the proportion
of patients with a 35-point increase in heart failure disease-specific
health status on the Kansas City Cardiomyopathy Questionnaire
(KCCQ) overall simmer score or a 320% decrease in NT-proBNP. In
this study, there was no significant difference in NT-proBNP levels
between the dapagliflozin and placebo groups. However, for the
other primary outcome, the dapagliflozin group showed significant
improvement as compared to the placebo group [17].
Both these trials strongly suggest a SGLT2 inhibitor has beneficial
effects in patients of HFrEF, irrespective of their diabetic status. The
finding that dapagliflozin is as effective in patients without T2DM as
in those with the disease suggests the beneficial effects of SGLT2
inhibitors on heart failure are exerted through mechanisms other
than those reflecting improvement of metabolic disorders specific to
T2DM, such as lowering of blood glucose. Further evaluation of the
mechanisms underlying the beneficial effects of SGLT2 inhibitors on
patients with HFrEF is necessary. At present, several other clinical
trials are underway to validate the efficacy of SGLT2 inhibitors in
heart failure patients, including those with HFpEF. The trial names
and their overviews are listed in Table 1. The information obtained
from these studies may provide the impetus to change the treatment
of heart failure in the near future.
Mechanisms thought likely to underlie the cardioprotective
effects of SGLT2 inhibitors
In the DAPA-HF study, the reductions in cardiovascular death
and hospitalization for heart failure in the dapagliflozin group
were observed in patients with or without T2DM. This suggests the
beneficial effects of SGLT2 inhibitors on heart failure patients are
mediated by mechanisms other than glycemic reduction and
correction of T2DM-related metabolic disorder. The mechanisms
currently thought likely to underlie the cardioprotective effects of
SGLT2 inhibitors are described below (Fig. 1).
Blood pressure reduction and diuresis
Two major factors contributing to the cardioprotective
effects of SGLT2 inhibitors are their blood pressure lowering
and diuretic effects. The primary effects of SGLT2 inhibition are
reductions in glucose and Na+ reabsorption in the proximal
tubule. Most likely both the natriuresis and the osmotic effect of
glucosuria are involved in the diuretic effect of SGLT2 inhibitors
with a resultant contraction of plasma volume [18]. The
natriuresis induced by SGLT2 inhibitors is thought to be
transient, but the decreases in systolic (5–6 mmHg) and
diastolic (1–2 mmHg) blood pressure are sustained, as was
shown in the EMPA-REG OUTCOME [8].
It is also known that blood pressure is closely related to the
onset of heart failure. The antihypertensive and lipid-lowering
treatment to prevent heart attack trial (ALLHAT) was a random-
ized, double-blind, active-controlled clinical trial [19]. This trial
enrolled 33,357 participants with hypertension and high cardio-
vascular disease risk to compare the efficacies of antihypertensive
drugs, including chlorthalidone, amlodipine, lisinopril, and
doxazosin, against coronary heart disease. As a secondary
outcome, the chlorthalidone group had a lower 6-year rate of
heart failure than either the amlodipine or lisinopril group.
Further analysis in the Heart Failure Validation Study of ALLHAT
[20] revealed that chrolthalidone reduced the risk of HFrEF to a
significantly greater degree than amlodipine or doxazosin, but
had an effect similar to lisinopril. In addition, chlorthalidone also
reduced the risk of HFpEF significantly more than amlodipine,
lisinopril, or doxazosin. These results demonstrated that
chlorthalidone, which has antihypertensive and diuretic effects,
prevents heart failure without distinguishing between HFrEF and
HFpEF.
The blood pressure lowering and diuretic effects of SGLT2
inhibitors may also contribute to the prevention of heart failure.
With respect to the diuretic effect of SGLT2 inhibitors, a difference
from the effect of loop diuretics has been suggested. In a
mathematical model, dapagliflozin produced a 2-fold greater
reduction in interstitial fluid volume than blood volume, while
bumetanide, a loop diuretic, reduced interstitial volume by only
78% of the reduction in blood volume, suggesting the interstitial-
dominant volume reducing effect of SGLT2 inhibitors may mediate
their beneficial effects preventing heart failure [21,22].
A randomized trial of intensive versus standard blood-pressure
control (SPRINT) [23] showed that among patients at high risk for
cardiovascular events, targeting a systolic blood pressure of
<120 mmHg as compared to <140 mmHg resulted in significantly
lower rates of cardiovascular events, predominantly a lower
incidence of heart failure. In the EMPA-REG OUTCOME, CANVAS
program, and DECLARE-TIMI 58 trial, systolic blood pressures in
the patients’ background profiles were around 130–140 mmHg,
and they were lowered by about 5 mmHg by the SGLT2 inhibitor.
This blood pressure lowering effect may contribute to the
suppression of cardiovascular events, especially the incidence of
heart failure.
In animal experiments, ipragliflozin, reportedly prevented LV
hypertrophy and fibrosis in non-diabetic obese rats with hyper-
tension (DS/obese rat) without affecting plasma glucose levels
[24]. Treatment of ipragliflozin ameliorated LV hypertrophy, and
changes in LV wall thickness and fibrosis in association with
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increased urine volume. In the ipragliflozin-treated group, systolic
blood pressure was lower than in the DS/obese control group at
11 weeks of age, without a significant difference in blood glucose,
insulin, or lipid levels; body weights; or heart rate.
Ketone body metabolism
A number of studies have reported that ketone levels are
elevated in T2DM patients treated with a SGLT2 inhibitor, although
Table 1
Ongoing outcome clinical trials of SGLT2 inhibitors for patients with heart failure.










HFpEF Age  40 years, NYHA class II-
IV, and medical history of
typical symptoms/signs of
heart failure  6 weeks,




for HF, must be off intravenous
HF medications for at least 24 h,
etc.
4700 Time to the first occurrence
of any of the components of
CV death, hospitalization






HFpEF Age  40 years, LVEF > 40% and
evidence of structural heart
disease, elevated NT-proBNP
levels, patients should receive
background standard of care,
etc.
500 Change from baseline in
6MWD at week 16, change







HFrEF Age  18 years, NYHA class II-IV
for at least 8 weeks, LVEF  40%
and evidence of structural heart
disease, elevated NT-proBNP
levels, etc.
313 Change from baseline in




HFrEF Age  18 years, optimal heart
failure therapy, LVEF  0.40,
eGFR > 30 ml/min/1.73 m2,
BMI < 45 kg/m2, NYHA class I-
III, etc.
190 Between-group difference








HFpEF Age  18 years, NYHA class II-IV
for at least 8 weeks, LVEF>40%,
elevated NT-proBNP levels,
structural heart disease within
6 or documented HHF within
12 months, etc.
5750 Time to first event of CV






HFrEF Age  18 years, NYHA class II-
IV, LVEF  40%, elevated NT-
proBNP levels, etc.
3730 Time to first event of CV






Age  18 years, NYHA class II-
IV. Cohort A; HFrEF, appropriate
dose of medical therapy for HF.
Cohort B HFpEF, elevated NT-
proBNP, structural heart
disease (LA enlargement and/or
LVH) by echo, Elevated NT-
proBNP, etc.
86 Change from baseline to
week 12 in PCr/ATP ratio in







HFpEF Age  18 years, NYHA class II-
IV, chronic HF with preserved
EF defined as LVEF > 40%,
elevated NT-proBNP, structural
heart disease documented by
echo, and/or documented
hospitalization for heart failure
within 12 months, etc.
315 Change of 6MWD from






HFrEF Age  18 years, NYHA class II-
IV, chronic HF with reduced EF
defined as LVEF  40%, etc.
312 Change of 6MWD from




HFpEF and HFrEF Age  18 years, currently
hospitalized for the primary
diagnosis of acute heart failure,
patients must be randomized
after at least 25 h and no later
than days after admission,
elevated NT-proBNP levels, etc.
500 Composite endpoint
composed of time to death,
number of heart failure
events (HFEs), time to first
HFE, change in KCCQ-CCS
from baseline after 90 days
of treatment
2021/7/3
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Hear Association; LVEF, left ventricular ejection
fraction; HF, heart failure; CV death, cardiovascular death; 6MWD, 6-minute walking distance; KCCQ-TSS, Kansas-City Cardiomyopathy Questionnaire-Total Symptom
Score; eGFR, estimated glomerular filtration ratio; HHF, hospitalization for heart failure; BMI, body mass index; PCr, phosphocreatine; MRS, magnetic resonance
spectroscopy; KCCQ-CCS, Kansas-City Cardiomyopathy Questionnaire-Clinical Summary Score.
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the mechanism is not completely clear [25–30]. In addition, several
reports have shown that cardiac uptake of ketone bodies is
significantly increased in patients with heart failure [31]. We
therefore suggest that SGLT2 inhibitors improve myocardial fuel
metabolism and cardiac efficiency by shifting fuel utilization away
from lipids and glucose to ketone bodies.
Nearly 95% of myocardial energy is derived from mitochondrial
oxidative metabolism and 5% from glycolysis and guanosine-5’-
triphosphate formation [32]. In the normal heart, fatty acids (60–
70%) and glucose (30%) are the major energy substrates [33], but
the heart can also take up and oxidize ketone bodies (b-hydro-
xybutyrate and acetoacetate) [33]. Plasma ketone bodies are
formed from fatty acids in the liver. Their concentration in arterial
plasma is normally very low, making them only a minor substrate
in the myocardium. Metabolic flexibility refers to the ability of
cardiac muscle to switch between free fatty acids and glucose as
the predominant fuel source based on substrate availability
[32]. During starvation or poorly controlled diabetes, the liver
converts free fatty acids to the ketone bodies, such as acetoacetate
and b-hydroxybutyrate, elevating plasma ketone body concentra-
tions secondary to low insulin and high fatty acids, and they
become a major substrate for the myocardium [33].
Ketone bodies serve as an alternative fuel and play a critical role
in human survival during periods of starvation, providing fat-
derived calories to the brain, heart, kidneys, and other vital tissues.
An advantage of ketone bodies is that more ATP is produced per
molecule of oxygen consumed than with glucose or free fatty acids,
which increases cardiac efficiency [32]. In the setting of the failing
heart, the myocardium is unable to optimally use canonical fuel.
Cardiac uptake of carbohydrate (glucose, lactate, and pyruvate) is
decreased, whereas uptake of total ketone bodies and b-hydro-
xybutyrate are increased, in diabetics as compared to non-
diabetics [34]. Moreover, there is a significant correlation between
the plasma BNP levels and cardiac uptake of total ketone bodies,
which suggests cardiac utilization of ketone bodies increases with
deterioration of LV function [34]. In addition, myocardial ketone
body utilization is preserved in advanced heart failure, although
skeletal-muscle ketone body utilization is impaired [35]. These
reports support the idea that increases in the plasma ketone body
concentration induced by SGLT2 inhibitors may protect failing
hearts in diabetic patients. However, further evaluation is needed
to clarify whether the protective effect of ketone bodies underlies
the cardioprotective effects of SGLT2 inhibitors in non-diabetic
patients with HFrEF. It also should be clarified whether the
increase in ketone bodies contributes to the prevention of HFpEF in
patients with T2DM.
Ketone bodies not only serve as an energy source, they also have
several functions related to intracellular signaling. For example,
b-hydroxybutyrate is known to be an endogenous inhibitor of
histone deacetylases (HDACs). These enzymes affect the acetyla-
tion status of histones and other important cellular proteins,
thereby playing an important role in the regulation of gene
expression. They are also recognized to be potentially useful
therapeutic targets in various human disorders, including patho-
logical cardiac remodeling [36]. Lkhagva et al. [37] reported that
HDAC inhibition improves cardiac function, reducing chamber size,
improving cardiac metabolism, and reducing inflammation in
failing rat hearts. It may be that HDAC inhibition by b-hydro-
xybutyrate leads to improved signaling in heart failure. It is
noteworthy, however, that cardiac-specific deletion of HDAC1 and
2 in developing mice is neonatally lethal due to cardiac
arrhythmias, dilated cardiomyopathy, and up-regulation of genes
encoding skeletal muscle-specific contractile proteins and Ca2+
channels [38].
b-hydroxybutyrate is also reported to be a ligand for G protein-
coupled receptor 41 (GPR41), which is also known as free fatty acid
receptor 3 (FFAR3). GPR41 is highly expressed within sympathetic
ganglia, and its inhibition by b-hydroxybutyrate reportedly
suppresses sympathetic nervous system activity and heart rates
[39]. This suggests ketone bodies directly regulate sympathetic
nerve activity, thereby controlling energy expenditure used to
maintain metabolic homeostasis. In addition, the crucial role
played by the sympathetic nervous system in the development of
heart failure suggests SGLT2 inhibitor-induced increases in
b-hydroxybutyrate may improve heart failure status by modulat-
ing sympathetic nerve activity.
Sodium-hydrogen exchanger
Recent studies suggest that SGLT2 inhibitors may reduce
intracellular Na+ load in failing cardiomyocytes by inhibiting
the sarcolemmal Na+/H+ exchanger (NHE) [18]. Because most
studies have shown that SGLT2 is not expressed in rodents [40]
or in human hearts, whether the subjects were healthy or
suffered from a pathological condition [41], it is not thought
that SGLT2 inhibitors act directly on cardiac myocytes. Recently,
however, empagliflozin was observed to directly modify
cytoplasmic Na+ and Ca2+ concentrations and the mitochondrial
Fig. 1. Mechanisms thought to underlie the cardioprotective effects of SGLT2 inhibitors.
eNOS, endothelial nitric oxide synthase; NHE, Na+/H+ exchanger; SGLT2, sodium-glucose cotransporter-2.
Y. Nakagawa, K. Kuwahara / Journal of Cardiology 76 (2020) 123–131128
Ca2+ concentration in isolated ventricular myocytes from
rabbits and rats by impairing NHE activity [42]. This effect
was independent of SGLT2 inhibition. NHE expression is
increased in heart failure, which appears to increase conversion
of pyruvate to lactate, leading to intracellular acidosis [18]. Ele-
vated cytoplasmic Na+ enhances mitochondrial Ca2+ extrusion,
as mitochondrial Ca2+ is exported from mitochondria into the
cytosol via the cytosolic Na+/Ca2+ exchanger. The mitochondrial
Ca2+ concentration is important not only for ATP production,
but also for preserving mitochondrial anti-oxidative capacity
[18]. A similar effect was shown for dapagliflozin and
canagliflozin in mouse cardiomyocytes and perfused mouse
hearts, suggesting this is a class effect of SGLT2 inhibitors
[43]. Several reports have demonstrated that decreasing the
intracellular Na+ concentration through NHE inhibition has a
cardioprotective effect [44,45]. Thus, SGLT2 inhibitors may
exert a protective effect by directly acting on the myocardium
through inhibition of NHE, without depending on SGLT2
inhibition.
Elevation of hemoglobin and hematocrit levels and erythropoietin
Treatment with an SGLT2 inhibitor leads to a modest increase in
hematocrit (2–4%) compared to placebo [46]. The increased
urinary volume induced by SGLT2 inhibitors returns to baseline
within 1 week, but the elevated hematocrit continues to increase
over 2 months [46]. In a study comparing the effects of
dapagliflozin and hydrochlorothiazide on hematocrit after
12 weeks, it was found that hematocrit was increased by 2.2%
(95% CI, 1.3% to 3.0%) in the dapagliflozin group, whereas it was
changed by 0.9% (95% CI, 2.3% to +0.6%) in the hydrochlorothi-
azide group [47]. This suggests the change in hematocrit induced
by SGLT2 inhibitors is not explained solely by hemoconcentration
due to diuresis. Indeed, increases in erythropoietin levels have
been reported after treatment of SGLT2 inhibitors. Lambers
Heersping et al. reported that serum erythropoietin levels are
transiently increased from baseline in the dapagliflozin group up to
week 4 of administration, followed by a gradual decline until week
12 [47]. In another trial, in which 6 months of empagliflozin
treatment was associated with a significant reduction in the LV
mass index, erythropoietin levels were significantly increased after
1 month of empagliflozin treatment as compared to placebo
(adjusted mean difference at 1 month 3.86 mIU/ml; 95% CI,
0.99 mIU/ml to 6.74 mIU/ml, p < 0.05; at 6 months 1.91 mIU/ml;
95% CI, 0.96 mIU/ml to 4.78 mIU/ml) [48]. It was also reported
that empagliflozin treatment was associated with an early increase
in plasma erythropoietin levels accompanied by an increase in
hematocrit in people with T2DM and coronary artery disease
[48]. Erythropoietin is produced by “neural crest-derived”
fibroblasts residing near the proximal tubules in the kidney
[46]. Selective proximal tubule injury induces transdifferentiation
of erythropoietin-producing fibroblasts into myofibroblasts,
resulting in a reduction in erythropoietin production [49]. Reab-
sorption of Na+ with glucose via SGLT2 in the proximal tubular
epithelial cells is followed by consumption of ATP for Na+/K+
ATPase, which extrudes Na+ by replacing it with K+. Excess Na+
absorption via SGLT2 observed in T2DM may promote a hypoxic
state and deterioration of the proximal tubules. SGLT2 inhibitors
suppress Na+ reabsorption, reduce ATP consumption by Na+/K+
ATPase, and improve relative hypoxic conditions in the proximal
tubules. This may allow reversion of myofibroblasts to erythro-
poietin-producing fibroblasts, resulting in enhancement of hema-
topoiesis [46]. In the DAPA-HF trial, the beneficial effects of
dapagliflozin on the outcomes of heart failure patients were
similar in patients with or without T2DM. In that trial, hematocrit
levels were increased by about 2% in the dapagliflozin group [9],
which may reflect dapagliflozin-induced elevation of erythropoie-
tin levels.
It should be noted, however, that erythropoiesis-stimulating
agents (ESAs) have failed to improve clinical outcomes in heart
failure. The effects of ESAs on heart failure outcomes were
examined in the RED-HF (Reduction of Events by Darbepoetin Alfa
in Hear Failure) trial, in which 2278 patients were enrolled
[50]. Median hemoglobin levels were increased, but no beneficial
effect of ESA was observed on the primary composite endpoint of
death and hospitalization with worsening heart failure or any of
the other endpoints. To the contrary, ischemic stroke and embolic/
thrombotic events were increased in the ESA group [51]. But
because the increase in endogenous erythropoietin levels with
administration of a SGLT2 inhibitor may differ from the increase
elicited by exogenous administration of ESA, the possibility that
the cardioprotective effects are mediated via SLGT2 inhibitor-
induced erythropoietin cannot be excluded. Further examination is
needed to verify the contribution of increased erythropoietin and
enhanced hematopoiesis to the cardioprotective effects induced by
SGLT2 inhibition.
Sympathetic nerve activity
Despite the reductions in blood pressure and plasma volume,
heart rate was also decreased somewhat in the empagliflozin
group in EMPA-REG OUTCOME. In a subanalysis of three placebo-
controlled, double-blind studies of luseogliflozin, treatment with
luseogliflozin elicited significant reductions in heart rate from
baseline in patients with relatively high heart rates [52]. We
therefore suggest that SGLT2 inhibitors suppress sympathetic
nerve activity. Activation of the sympathetic nervous system is
closely related to the onset and progression of heart failure. In
addition, b-blockers are standard therapy for patients with HFrEF.
The suppressive effect of SGLT2 inhibitors on sympathetic nerve
activity may thus be protective in failing hearts. The mechanism by
which SGLT2 inhibitors suppress sympathetic nerve activity is not
yet fully understood, although one possible explanation is
described above in the section on “Ketone body metabolism.”
Activation of endothelial nitric oxide synthase
Acute canagliflozin treatment significantly reduced myocardial
infarct size, serum troponin-T levels, and LV dysfunction in a non-
diabetic mouse myocardial ischemia/reperfusion injury model
[53]. Canagliflozin also significantly increased endothelial nitric
oxide synthase (eNOS) during ischemia/reperfusion, thereby
enhancing endothelium-dependent vasodilation [53]. In addition,
empagliflozin ameliorated high glucose-induced increases in
endothelial cell senescence markers and oxidative stress, and
decreased eNOS expression and nitric oxide formation [54]. These
effects of SGLT2 inhibitors on endothelium-dependent vasodila-
tion and eNOS activity may contribute to their cardioprotective
efficacy.
Conclusion
The beneficial effects of SGLT2 inhibitors preventing macro-
vascular events and hospitalization for heart failure were shown in
three landmark trials; EMPA-REG OUTCOME, the CANVAS program,
and the DECLARE-RTIM58 trial. More recently, the DAPA-HF trial,
which showed that dapagliflozin significantly improved the out-
comes of patients with HFrEF, irrespective of the presence orabsence
of T2DM, demonstrated the significance of SGLT2 inhibitors as novel
therapeutic agents in heart failure. We anticipate that further
research will provide additional insight into the clinical importance
of these drugs to the treatment of heart failure, including both HFpEF
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and acute decompensated heart failure, as well as the mechanisms
underlying their clinical benefits.
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